Cited by 28Fatty Acid Research and HealthLipoproteins and Cardiovascular HealthLipid metabolism and disorders

Prescription Omega-3-Acid Ethyl Esters for the Treatment of Very High Triglycerides

Sadovsky, Richard, Kris-Etherton, Penny·2009·Postgraduate Medicine

Abstract

Triglyceride (TG) levels can increase for numerous reasons, including a sedentary lifestyle, an unhealthy diet, especially one rich in refined carbohydrates, and comorbidities. According to the National Cholesterol Education Program (NCEP), the normal TG level is or = 500 mg/dL) should be promptly managed and treated to reach lipid treatment goals, as determined by the NCEP. Lowering TG levels is the primary management goal in these patients, while lowering low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol levels are secondary goals. Therapeutic lifestyle changes are often recommended initially for patients with elevated TGs; however, concomitant drug therapy is often required. Data show that intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can significantly decrease serum TGs, along with plasma concentrations of certain lipoproteins. Omega-3-acid ethyl esters are available by prescription or as dietary supplements. Clinical trials in adult patients with VHTGs show that four 1 g capsules of prescription omega-3 fatty acids, which contain 465 mg of EPA and 375 mg of DHA per capsule, can effectively decrease TG levels by up to 45%, and is generally well tolerated.

Integrity signals

Registry

Crossref · 10.3810/pgm.2009.07.2020

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sadovsky, R., & Kris-Etherton, P.
Venue
Postgraduate Medicine
Published
2009-07
Volume
121
Issue
4
Pages
145-153
ISSN
  • 0032-5481 (ISSN-L)
  • 1941-9260
OpenAlex
W1976476281
Cited by
28
References
4
Citations by year
2023: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 5 · 2013: 4 · 2012: 6
FWCI
4.52
Type
journal article
Language
en
Open access
closed
Locations
  • Postgraduate Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
omega-3 acid ethyl esters, hypertriglyceridemia, eicosapentaenoic acid, docosahexaenoic acid, triglyceride lowering, lipid-lowering therapy, dietary supplements, therapeutic lifestyle changes, drug tolerability
MeSH terms
Diet, Docosahexaenoic Acids, Drug Combinations, Humans, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review